Senators lambast new Alzheimer’s drug’s price but give Janet Woodcock a free pass on the approval decision

Senate Finance Democrats took aim at Biogen’s pricey new Alzheimer’s drug on Thursday, but members on both sides of the aisle at a separate appropriations hearing didn’t question acting FDA commissioner Janet Woodcock on the approval.